1. Home
  2. RYTM vs MTG Comparison

RYTM vs MTG Comparison

Compare RYTM & MTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • MTG
  • Stock Information
  • Founded
  • RYTM 2008
  • MTG 1957
  • Country
  • RYTM United States
  • MTG United States
  • Employees
  • RYTM N/A
  • MTG N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • MTG Property-Casualty Insurers
  • Sector
  • RYTM Health Care
  • MTG Finance
  • Exchange
  • RYTM Nasdaq
  • MTG Nasdaq
  • Market Cap
  • RYTM 6.4B
  • MTG 6.4B
  • IPO Year
  • RYTM 2017
  • MTG 1991
  • Fundamental
  • Price
  • RYTM $98.54
  • MTG $28.52
  • Analyst Decision
  • RYTM Strong Buy
  • MTG Hold
  • Analyst Count
  • RYTM 12
  • MTG 5
  • Target Price
  • RYTM $117.00
  • MTG $26.80
  • AVG Volume (30 Days)
  • RYTM 629.6K
  • MTG 1.7M
  • Earning Date
  • RYTM 11-04-2025
  • MTG 10-29-2025
  • Dividend Yield
  • RYTM N/A
  • MTG 2.11%
  • EPS Growth
  • RYTM N/A
  • MTG 9.77
  • EPS
  • RYTM N/A
  • MTG 3.11
  • Revenue
  • RYTM $174,334,000.00
  • MTG $1,216,428,000.00
  • Revenue This Year
  • RYTM $46.10
  • MTG $2.34
  • Revenue Next Year
  • RYTM $63.02
  • MTG $3.48
  • P/E Ratio
  • RYTM N/A
  • MTG $9.16
  • Revenue Growth
  • RYTM 54.92
  • MTG 2.20
  • 52 Week Low
  • RYTM $45.91
  • MTG $21.94
  • 52 Week High
  • RYTM $116.00
  • MTG $29.01
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 39.87
  • MTG 61.64
  • Support Level
  • RYTM $95.27
  • MTG $27.19
  • Resistance Level
  • RYTM $102.20
  • MTG $28.18
  • Average True Range (ATR)
  • RYTM 4.86
  • MTG 0.56
  • MACD
  • RYTM -1.75
  • MTG 0.16
  • Stochastic Oscillator
  • RYTM 17.51
  • MTG 96.27

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About MTG MGIC Investment Corporation

MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection accounts for close to majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia and New York.

Share on Social Networks: